Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Schrum

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2026
Addressing Common Medications That Influence Immunotherapy Response in Solid TumorsNicholas DeVito, Erica Gray, Daniel Schrum, et al.
Journal of Medical Virology|April 28, 2026
Respiratory Viral Infections Following CD19 CAR T-Cell TherapyJulian J Weiss, Julia Messina, Jennifer Saullo, et al.
Transplantation and Cellular Therapy|February 20, 2026
Musculoskeletal Adverse Events Following BCMA CAR-T Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune CorrelatesAmber Feng, Jian Wu, Taewoong Choi, et al.
Blood Cancer Journal|May 9, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumOren Pasvolsky, Danai Dima, Lei Feng, et al.
Blood Cancer Journal|November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experienceAimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2026
Addressing Common Medications That Influence Immunotherapy Response in Solid TumorsNicholas DeVito, Erica Gray, Daniel Schrum, et al.
Journal of Medical Virology|April 28, 2026
Respiratory Viral Infections Following CD19 CAR T-Cell TherapyJulian J Weiss, Julia Messina, Jennifer Saullo, et al.
Transplantation and Cellular Therapy|February 20, 2026
Musculoskeletal Adverse Events Following BCMA CAR-T Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune CorrelatesAmber Feng, Jian Wu, Taewoong Choi, et al.
Blood Cancer Journal|May 9, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumOren Pasvolsky, Danai Dima, Lei Feng, et al.
Blood Cancer Journal|November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experienceAimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Pageof 1